The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALPMF | -4.6% | -10.19% | -2.12% | -61% |
| S&P | +14.5% | +93.32% | +14.09% | +570% |
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.50B | 15.3% |
| Gross Profit | $2.62B | 17.5% |
| Gross Margin | 74.77% | 1.4% |
| Market Cap | $17.20B | 1.7% |
| Market Cap / Employee | $1.26M | 0.0% |
| Employees | 13.6K | -7.5% |
| Net Income | $473.54M | 96.2% |
| EBITDA | $1.09B | 63.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.49B | -20.8% |
| Accounts Receivable | $4.63B | 26.7% |
| Inventory | 2.1K | 33.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.86B | 13.2% |
| Short Term Debt | $2.29B | -32.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 2.44% | 1.9% |
| Return On Invested Capital | 5.24% | -2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $297.90M | 19161.9% |
| Operating Free Cash Flow | $386.54M | 323.1% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 167.82 | 57.89 | 52.09 | 31.09 | -83.28% |
| Price to Book | 1.92 | 1.65 | 1.84 | 1.70 | 5.98% |
| Price to Sales | 1.76 | 1.42 | 1.38 | 1.35 | -13.12% |
| Price to Tangible Book Value | -11.93 | -13.21 | -18.25 | -100.19 | 982.63% |
| Price to Free Cash Flow TTM | 83.85 | 319.95 | 74.29 | 37.12 | -69.85% |
| Enterprise Value to EBITDA | 34.98 | 26.70 | 30.99 | 20.46 | -40.09% |
| Free Cash Flow Yield | 1.2% | 0.3% | 1.3% | 2.7% | 231.73% |
| Return on Equity | 3.3% | -3.8% | 3.2% | 5.5% | 453.87% |
| Total Debt | $7.26B | $6.57B | $6.27B | $6.16B | -9.82% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
